The Upcoming
  • Cinema & Tv
    • Movie reviews
    • Film festivals
      • Berlin
      • Tribeca
      • Sundance London
      • Cannes
      • Locarno
      • Venice
      • London
      • Toronto
    • Show reviews
  • Music
    • Live music
  • Food & Drinks
    • News & Features
    • Restaurant & bar reviews
    • Interviews & Recipes
  • Theatre
  • Art
  • Travel & Lifestyle
  • Literature
  • Fashion & Beauty
    • Accessories
    • Beauty
    • News & Features
    • Shopping & Trends
    • Tips & How-tos
    • Fashion weeks
      • London Fashion Week
      • London Fashion Week Men’s
      • New York Fashion Week
      • Milan Fashion Week
      • Paris Fashion Week
      • Haute Couture
  • Join us
    • Editorial unit
    • Our writers
    • Join the team
    • Join the mailing list
    • Support us
    • Contact us
  • Competitions
  • Facebook

  • Twitter

  • Instagram

  • YouTube

  • RSS

Current affairsNewsScience, Health & Technology

Breast cancer drug turned down for NHS deemed too expensive

Breast cancer drug turned down for NHS deemed too expensive
23 April 2014
Samantha Waite
Avatar
Samantha Waite
23 April 2014

A breast cancer drug that can prolong life by nearly six months has been deemed too expensive and turned down for the NHS.

The drug, called Kadcyla (generic name trastuzumab emtansine), costs approximately £90,000 per patient but offers to extend life by almost six months.

The National Institute for Health and Care Excellence (NICE), which sets the guidelines for England and Wales, believes that the drug is not effective enough to support the large sum.

The watchdog is consulting the manufacturer Roche to reduce its’ costs and give NHS patients free access to it.

NICE justified the decision, telling the Guardian “the reality is that given its price and what it offers to patients, it will displace more health benefits, which the NHS could achieve in other ways, than it will offer to patients with breast cancer.”

The decision has been heavily criticised by both breast cancer charities and Roche.

Speaking to the Huffington Post, chief executive of NICE Sir Andrew Dillon said: “Roche would act in the best interest of patients and use the consultation period to look again at their evidence and consider if there was more they could do.”

The drug is available in England via the government’s Cancer Drugs Fund (CDF). But the scheme will soon end in 2016 and patients in England will no longer be able to get Kadcyla through the NHS.

Although, Kadcyla isn’t a cure, it prolongs life by a median of 5.8 months. The drug combines Herceptin (trastuzamab) with a chemotherapy agent and is a new medicine for those with HER 2-positive secondary breast cancer and has fewer side effects than other drugs.

Studies show that Kadcyla has a survival rate of 30.9 months compared with 25.1 months for patients on lapatinib and capecitabine.

Professor Paul Ellis, a consultant oncologist at King’s College London, who worked on the drug trials said: “Kadcyla represents a significant advance in HER 2-positive breast cancer, so for NICE to issue negative preliminary guidance is a huge blow.”

Back in 2010, NICE rejected another breast cancer drug Lapatinib, also known as Tyverb, on the basis of costs, which is now widely used and highly successful with cancer patients.

Samantha Waite

Related ItemsBreast cancercancercancer drugmedicine

More in Current Affairs

Women of Ireland have rolled over for long enough: The 8th and the long walk to abortion rights

Emma Kiely
Read More

Changes to expect during menopause

The editorial unit
Read More

Why Equity Linked Savings Schemes is a preferred tax saving?

The editorial unit
Read More

How the world’s top designers would rebrand political parties

The editorial unit
Read More

Royal baby furore: Proof that the British monarchy is still popular?

Eoin O’Sullivan-Harris
Read More

World Mental Health Day 2018: Raising awareness and combating stigma

The editorial unit
Read More

Seven political personalities you should know about

The editorial unit
Read More

Donald Trump: An enemy of the arts?

The editorial unit
Read More

Trump’s fortune: Where did the money come from?

The editorial unit
Read More
Scroll for more
Tap
  • Popular

  • Latest

  • TOP PICKS

  • Alice Cooper at the O2 Arena
    ★★★★★
    Live music
  • Decision to Leave (Heojil Kyolshim)
    ★★★★★
    Cannes
  • The Innocent (L’Innocent)
    ★★★★★
    Cannes
  • Stephen Fry enters the Radio Times Hall of Fame in conversation with Alan Yentob at the BFI Imax
    Cinema & Tv
  • Roma Bar Show returns for a second edition in Rome next week
    Food & Drinks
  • “It was a really precious process”: An interview with Maksym Nakonechnyi on Butterfly Vision
    Cannes
  • Stranger Things: Season Four
    ★★★★★
    netflix
  • Henry VIII at Shakespeare’s Globe
    ★★★★★
    Theatre
  • Stars at Noon
    ★★★★★
    Cannes
  • Nostalgia
    ★★★★★
    Cannes
  • Nostalgia
    ★★★★★
    Cannes
  • Fiend in Notting Hill: “Risks that pay off”
    Food & Drinks
  • Alice Cooper at the O2 Arena
    ★★★★★
    Live music
  • Michael Kiwanuka at Alexandra Palace
    ★★★★★
    Live music
  • The Innocent (L’Innocent)
    ★★★★★
    Cannes
The Upcoming
Pages
  • Contact us
  • Join mailing list
  • Join us
  • Our London food map
  • Our writers
  • Support us
  • What, when, why
With the support from:
International driving license

Copyright © 2011-2020 FL Media

New family justice reforms introduced in England and Wales
Dying cancer patient raises £1million after bidding farewell on Facebook